GO
Loading...

Gilead Sciences Inc

More

  • *Gilead plans to sell Sovaldi in India for $300 per month. NEW DELHI/ MUMBAI, Sept 15- U.S. drugmaker Gilead Sciences Inc has agreed to license its hepatitis C drug Sovaldi to seven India- based drugmakers to sell cheaper versions of the $1,000- a-pill medicine in 91 developing nations including India.

  • Gilead to license generic version of Sovaldi Monday, 15 Sep 2014 | 7:40 AM ET

    Gilead Sciences has reached a deal with several generic drugmakers to produce a cheaper version of its popular, $1,000- per-pill hepatitis C drug Sovaldi for use in developing countries.

  • LOS ANGELES, Sept 12- The next generation version of Gilead Sciences Inc's $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive.

  • Final Glance: Biotechnology companies Friday, 12 Sep 2014 | 6:02 PM ET

    Amgen Inc. fell $1.07 or. 8 percent, to $137.89. Biogen Idec fell $3.72 or 1.1 percent, to $323.39. Celgene Corp. fell$. 44 or. 5 percent, to $91.52.

  • Most active Nasdaq-traded stocks Friday, 12 Sep 2014 | 1:19 PM ET

    Apple Inc. rose. 2 percent to $101.66 with 60,867,000 shares traded. Cisco Systems Inc. fell. 1 percent to $25.16 with 31,665,700 shares traded. eBay Inc. rose 3.0 percent to $52.19 with 42,136,100 shares traded.

  • Midday Glance: Biotechnology companies Friday, 12 Sep 2014 | 1:19 PM ET

    Amgen Inc. fell $1.38 or 1.0 percent, to $137.58. Biogen Idec fell $3.24 or 1.0 percent, to $323.87. Celgene Corp. fell$. 40 or. 4 percent, to $91.56.

  • Early Glance: Biotechnology companies Friday, 12 Sep 2014 | 11:13 AM ET

    Amgen Inc. fell$. 59 or. 4 percent, to $138.38. Biogen Idec fell $2.52 or. 8 percent, to $324.59. Celgene Corp. fell$. 13 or. 1 percent, to $91.83.

  • Final Glance: Biotechnology companies Thursday, 11 Sep 2014 | 6:02 PM ET

    Amgen Inc. fell$. 23 or. 2 percent, to $138.96. Biogen Idec fell $4.97 or 1.5 percent, to $327.11. Celgene Corp. fell $2.13 or 2.3 percent, to $91.96.

  • NEW YORK, Sept 11- U.S. stocks were down slightly in late afternoon trading on Thursday following a decline in biotechnology shares, but gains in financials helped to limit the day's losses. Shares of JPMorgan Chase were up 0.8 percent, while shares of Bank of America were up 1.1 percent, the two biggest positives on the S&P 500..

  • Midday Glance: Biotechnology companies Thursday, 11 Sep 2014 | 2:09 PM ET

    Amgen Inc. fell$. 83 or. 6 percent, to $138.36. Biogen Idec fell $6.31 or 1.9 percent, to $325.77. Celgene Corp. fell $2.51 or 2.7 percent, to $91.58.

  • Early Glance: Biotechnology companies Thursday, 11 Sep 2014 | 10:29 AM ET

    Amgen Inc. rose$. 03 or percent, to $139.22. Biogen Idec fell $1.85 or. 6 percent, to $330.23. Celgene Corp. fell$. 88 or. 9 percent, to $93.21.

  • Final Glance: Biotechnology companies Wednesday, 10 Sep 2014 | 6:16 PM ET

    Amgen Inc. rose $1.80 or 1.3 percent, to $139.19. Biogen Idec rose $5.25 or 1.6 percent, to $332.08. Celgene Corp. rose $1.16 or 1.2 percent, to $94.09.

  • Midday Glance: Biotechnology companies Wednesday, 10 Sep 2014 | 1:21 PM ET

    Amgen Inc. rose $1.34 or 1.0 percent, to $138.73. Biogen Idec rose $5.43 or 1.7 percent, to $332.26. Celgene Corp. rose$. 98 or 1.1 percent, to $93.91.

  • Final Glance: Biotechnology companies Tuesday, 9 Sep 2014 | 8:15 PM ET

    Amgen Inc. fell $1.88 or 1.3 percent, to $137.39. Biogen Idec fell $4.48 or 1.4 percent, to $326.83. Celgene Corp. fell $1.10 or 1.2 percent, to $92.93.

  • Midday Glance: Biotechnology companies Tuesday, 9 Sep 2014 | 1:22 PM ET

    Amgen Inc. fell $1.30 or. 9 percent, to $137.97. Biogen Idec fell $3.17 or 1.0 percent, to $328.14. Celgene Corp. fell $1.10 or 1.2 percent, to $92.93.

  • Early Glance: Biotechnology companies Tuesday, 9 Sep 2014 | 10:26 AM ET

    Amgen Inc. fell $1.63 or 1.2 percent, to $137.64. Biogen Idec fell $2.88 or. 9 percent, to $328.43. Celgene Corp. fell $1.24 or 1.3 percent, to $92.79.

  • Final Glance: Biotechnology companies Monday, 8 Sep 2014 | 6:38 PM ET

    Amgen Inc. rose $1.39 or 1.0 percent, to $139.27. Biogen Idec rose$. 83 or. 3 percent, to $331.31. Celgene Corp. rose$. 24 or. 3 percent, to $94.03.

  • Can anything slow Gilead down? Analysts say no Monday, 8 Sep 2014 | 3:12 PM ET
    Darryl Kato, research scientist for Gilead Sciences, works on the synthesis of a potential hepatitis C virus drug candidate at the company's lab in Foster City, California, Feb. 8, 2012.

    Gilead is already among the 10 best performers in the Nasdaq 100 this year. So can anything slow this behemoth down? If you ask the analysts, it sounds unlikely.

  • Midday Glance: Biotechnology companies Monday, 8 Sep 2014 | 1:36 PM ET

    Amgen Inc. rose$. 71 or. 5 percent, to $138.59. Biogen Idec fell $1.98 or. 6 percent, to $328.50. Celgene Corp. fell$. 12 or. 1 percent, to $93.67.

  • Early Glance: Biotechnology companies Monday, 8 Sep 2014 | 10:34 AM ET

    Amgen Inc. rose$. 97 or. 7 percent, to $138.85. Biogen Idec fell $1.58 or. 5 percent, to $328.90. Celgene Corp. fell$. 08 or. 1 percent, to $93.71.